Clinical trials
HER2 Positive clinical trials
Below are recruiting her2 positive clinical trials, each written for real people, not researchers. We’re tracking 344 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07615751RecruitingPhase 3
New drug combination for advanced HER2-positive breast cancer
This trial tests whether a newer drug called dalpiciclib works better than chemotherapy when combined with two other anti-HER2 drugs (pyrotinib and trastuzumab) for advanced breast cancer that has spread. The goal is to find a treatment that works well with fewer side effects.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07613151Recruiting
Lobular breast cancer with low hormone receptors
This study looks at a rare type of breast cancer called invasive lobular carcinoma that has low or no hormone receptors. The goal is to learn more about how this cancer behaves, which may help improve future treatments.
PadovaAges 18 years+ - NCT05891561RecruitingPhase 2
Short antibody treatment after surgery for early HER2+ breast cancer
This Phase 2 study tests a shorter schedule of trastuzumab and pertuzumab combined with chemotherapy (taxanes) to reduce breast cancer coming back after surgery. It mainly helps people with early-stage, HER2-positive breast cancer that has not spread, by testing whether a shorter plan still works well and is tolerable.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07593196Recruiting
Real-world study of her2-positive metastatic breast cancer in Kazakhstan
This study looks at real-world data from people with HER2-positive metastatic breast cancer in Kazakhstan to understand how anti-HER2 treatments (other than trastuzumab deruxtecan) are used and how well they work. If you were diagnosed between 2022 and 2023, this research may help improve future care.
Oral, KazakhstanAges 18–99 - NCT06276868RecruitingPhase 2
Darsilide plus hormone therapy and double antibody for breast cancer
This trial tests if adding a new drug (darsilide) to standard hormone therapy and two antibodies (trastuzumab and pertuzumab) before surgery can improve outcomes for women with HR-positive, HER2-positive breast cancer that hasn't spread.
Henan, HenanAges 18–70 - NCT06561555RecruitingPhase 2
Testing a new drug for advanced HER2-positive Paget's disease
This trial tests an investigational drug called Disitamab Vedotin for people with advanced Paget's disease that tests positive for HER2. It aims to see if the drug can shrink tumors or improve skin lesions.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06767449Recruiting
Zolbetuximab for Claudin18.2 positive stomach cancer
This trial is for people with advanced stomach cancer that has a specific protein called Claudin18.2 and is HER2-negative. It tests whether continuing zolbetuximab—a drug that targets this protein—can help control the cancer.
SeoulAges 19 years+ - NCT06770296RecruitingPhase 1
Finding the best dose of pyrotinib for first-line advanced HER2 breast cancer
This study tests a new way to give pyrotinib, a targeted pill for HER2-positive breast cancer, to people whose cancer has spread or come back and who have not had other treatments for this stage. The goal is to find the best dose to control cancer while managing side effects.
Nanjing, JiangsuAges 18–75 - NCT07405476RecruitingPhase 2
Zanidatamab before surgery for HER2 positive colon or rectal cancer
This trial tests if the drug zanidatamab, given before surgery, can help treat colon or rectal cancer that has a specific marker called HER2. The goal is to see if this approach can shrink tumors and improve outcomes for people whose cancer has not spread to other parts of the body.
Atlanta, GeorgiaAges 18 years+ - NCT07371585RecruitingPhase 2
Trastuzumab Deruxtecan for first-line HER2-positive advanced breast cancer
This trial tests a targeted therapy called Trastuzumab Deruxtecan (T-DXd) for people with HER2-positive breast cancer that has spread or cannot be removed. It is for those who have not yet received any chemotherapy or HER2-targeted treatment for metastatic disease. The study also focuses on managing side effects early, using digital tools to track symptoms.
VillejuifAges 18 years+ - NCT06856200Recruiting
Sirolimus plus palbociclib and fulvestrant for advanced breast cancer
This trial tests a new combination of three drugs (sirolimus, palbociclib, and fulvestrant) for people with a certain type of advanced breast cancer that is hormone receptor-positive and HER2-negative. The goal is to see if adding sirolimus can help control the cancer when standard hormone therapy is no longer working.
ShanghaiAges 18 years+ - NCT06035679Recruiting
Combination therapy before surgery for HER2-positive breast cancer
This trial tests a combination of targeted therapies and chemotherapy given before surgery for HER2-positive breast cancer. It aims to see if this approach helps shrink tumors and improve outcomes.
Fuzhou, FujianAges 18–75 - NCT07296705RecruitingPhase 2
New drug combo to save the bladder in HER2-positive bladder cancer
This trial tests combining two newer drugs (zanidatamab and tislelizumab) with standard chemotherapy before bladder surgery. The goal is to shrink the tumor so the bladder can be saved instead of removed.
Fuzhou, FujianAges 18–85 - NCT05816655RecruitingPhase 2
Test two hormone treatment combinations for metastatic breast cancer
This Phase 2 study compares two combinations of hormone-blocking drugs plus an anti-cancer targeted pill to see which works better for hormone-receptor positive, HER2-negative metastatic breast cancer. It may help by finding a more effective treatment plan when the cancer has spread.
SeoulAges 19–80 - NCT07281001Recruiting
Trastuzumab deruxtecan study for breast cancer patients
This study looks at how well the drug trastuzumab deruxtecan works in women with breast cancer that has spread. It is for patients who have already taken this drug.
MoscowAges 18–80 - NCT07263425RecruitingPhase 2
Study of thiotepa and trastuzumab for breast cancer that spread to the lining of the brain and spinal cord
This trial tests a combination of two drugs given through a special port in the head to treat HER2-positive breast cancer that has spread to the layer covering the brain and spinal cord (leptomeningeal metastasis). It aims to see if this treatment is safe and effective.
Nanjing, JiangsuAges 18–75 - NCT07233499RecruitingPhase 2
Nebivolol for heart protection during breast cancer treatment
This trial tests if the drug nebivolol can protect the heart from damage caused by trastuzumab (Herceptin) in women with HER2-positive breast cancer. If effective, it may help prevent heart problems while still allowing cancer treatment.
CairoAges 18–65 - NCT07205822RecruitingPhase 3
Dato-DXd for advanced HR-positive, HER2-low breast cancer
This trial tests a new drug called Dato-DXd for people with a certain type of advanced breast cancer that has stopped responding to hormone therapy. The drug targets a protein on cancer cells to help stop the cancer from growing.
Largo, FloridaAges 18 years+ - NCT06669975RecruitingPhase 1/Phase 2
Testing AP402 for her2-positive advanced solid tumors
This trial tests an experimental drug called AP402 for people with HER2-positive solid tumors that have spread or cannot be removed by surgery, and who have no standard treatment options left. The goal is to see if AP402 can shrink tumors or slow their growth.
Macquarie, New South WalesAges 18 years+ - NCT07180082RecruitingPhase 2
Pyrotinib for HER2-positive advanced breast cancer
This trial tests whether taking pyrotinib continuously or intermittently can help people with HER2-positive advanced breast cancer that has spread. It is for those who have already received prior treatment for their advanced disease.
ShanghaiAges 18 years+ - NCT06207734RecruitingPhase 2
Stopping CDK4/6 inhibitors in advanced breast cancer
This trial looks at what happens when women with advanced hormone-positive, HER2-negative breast cancer stop taking a CDK4/6 inhibitor after at least a year of successful treatment. The goal is to see if it's safe to take a break from the CDK4/6 inhibitor while continuing hormone therapy alone.
BerlinAges 18 years+ - NCT07152405RecruitingPhase 3
New drug vs. chemo for HER2+ stomach cancer
This trial tests a new targeted drug, BL-M07D1, against standard chemotherapy for people with HER2-positive stomach or gastroesophageal junction cancer that has spread. The goal is to see if BL-M07D1 works better than standard chemo.
Harbin, HeilongjiangAges 18–75 - NCT06958627RecruitingPhase 2/Phase 3
Smart phone app vs standard care for breast cancer treatment
This trial tests whether a smartphone-based patient management program helps women with HER2-positive breast cancer take their medication (pyrotinib) more consistently compared to usual care. It may be a good fit if you are starting or continuing pyrotinib treatment.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07117864Recruiting
T-DXd with brain radiation for HER2+ breast cancer
This trial tests a new combination of a targeted drug (T-DXd) with brain radiation for women with breast cancer that has spread to the brain and is HER2-positive or HER2-low. The goal is to see if this approach is safe and works better than radiation alone.
Beijing, Beijing MunicipalityAges 18–75
Hear when a new HER2 Positive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her2 positive?
- Yes. Clin2 currently lists 344 recruiting her2 positive studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her2 positive trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her2 positive trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.